Glycemic variability determined with a continuous glucose monitoring system can predict prognosis after acute coronary syndrome

Table 6 Sensitivity analysis of Multiple logistic regression analysis for the prediction of MACCE in ACS patients

Variables	Multivariate (Model 1)			Multivariate (Model 2)			Multivariate (Model 3)
Variables	OR	95% CI	p-value	OR	95% CI	p-value	OR	95% CI	p-value
Patients with DM
Hypertension	0.435	0.157–1.145	0.092		–		0.438	0.105–6.510	0.105
Cre on admission, per 1 mg/dl	1.141	0.407–4.202	0.829		–		1.208	0.401–4.762	0.768
BNP during stable phase, per 1 pg/ml	1.002	0.999–1.005	0.053		–		1.002	0.999–1.005	0.072
HDLC, per 1 mg/dl	0.962	0.909–1.011	0.134		–		0.966	0.912–1.017	1.035
Glucose on admission > 180 mg/dl		–		2.415	0.861–7.232	0.094	2.038	0.660–6.666	0.217
HbA1c, per 1%		–		1.154	0.842–1.575	0.364	1.091	0.753–1.562	0.637
High MAGE		–		2.780	1.017–8.956	0.046	3.238	1.041–12.38	0.042
Patients with IGT
Multivessel disease	4.586	2.028–10.843	< 0.001		–		4.036	1.747–9.694	0.001
hs-CRP during stable phase > 0.1355 mg/dl	3.766	1.641–9.226	0.002		–		3.857	1.664–9.576	0.001
High MAGE		–		2.528	1.145–5.581	0.024	2.080	0.861–4.957	0.102

Patients with DM: Model 1 hypertension, Cre on admission, BNP during stable phase and HDLC, Model 2 glucose on admission > 180 mg/dl, HbA1c high MAGE, Model 3 all variables included in Model 1 and 2; Patients with IGT: Model 1 multivessel disease and hs-CRP during stable phase > 0.1355 mg/dl, Model 2 included only High MAGE, Model 3 all variables included in Model 1 and 2. Other abbreviations as in Tables 1, 2, 3, 4